Brief: Oncosil Medical Says Q3 Revenue Increased 49% VS PCP
28/04/2026 02:29
April 28 (Reuters) - Oncosil Medical Ltd OSL.AX: Q3 FY26 REVENUE INCREASED 49% VERSUS PCP Further company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval